We are live on ! Find out more
NAMS icon

NewAmsterdam Pharma

183 hedge funds and large institutions have $3.13B invested in NewAmsterdam Pharma in 2026 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 84 increasing their positions, 48 reducing their positions, and 35 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more repeat investments, than reductions

Existing positions increased: 84 | Existing positions reduced: 48

68% more capital inflows, than outflows

Capital inflows: $590M | Capital outflows: $350M

3.41% more ownership

Funds ownership: 104.36% → 107.77% (+3.4%)

6% less funds holding

Funds holding: 194 → 183 (-11)

17% less funds holding in top 10

Funds holding in top 10: 6 → 5 (-1)

19% less call options, than puts

Call options by funds: $38.2M | Put options by funds: $47M

26% less first-time investments, than exits

New positions opened: 26 | Existing positions closed: 35

Holders
183
Holders Change
-11
Holders Change %
-5.67%
% of All Funds
2.22%
Holding in Top 10
5
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-16.67%
% of All Funds
0.06%
New
26
Increased
84
Reduced
48
Closed
35
Calls
$38.2​M
Puts
$47​M
Net Calls
-⁠$8.81​M
Net Calls Change
+$64.5​M

NAMS Hedge Fund Activity: Q3 2026 in Review

183 of the 8,227 institutional investors tracked by Wall St. Rank reported a position in NewAmsterdam Pharma (NAMS) for Q3 2026, worth a combined $3.13B — down 24% from $4.13B a quarter earlier.

Sellers outnumbered buyers: 35 funds closed out of NAMS and 26 opened new positions — a net loss of 9 holders — while 48 trimmed existing stakes and 84 added.

The largest buyer was Orbis Allan Gray, adding an estimated $55.7M. The largest seller was Westfield Capital Management, exiting entirely with an estimated $52.1M sold.

  • 183 institutional investors held NewAmsterdam Pharma (NAMS) as of Q3 2026, down from 194 in Q2 2026.
  • Funds reported $3.13B of NewAmsterdam Pharma stock for Q3 2026, down 24% quarter-over-quarter.
  • 26 funds opened new NewAmsterdam Pharma positions in Q3 2026 and 35 closed out, a net change of -9 holders.
  • The largest NewAmsterdam Pharma buyer in Q3 2026 was Orbis Allan Gray, an estimated $55.7M added.
  • The largest NewAmsterdam Pharma seller in Q3 2026 was Westfield Capital Management, an estimated $52.1M sold.

Based on aggregated 13F filings for Q3 2026.